|
Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company, has announced its earnings for the first quarter of FY26.
In the first quarter of fiscal year 2026, the company demonstrated strong financial and business performance. Consolidated revenue saw a 7.4% year-over-year increase, driven by an impressive 11% growth in the domestic branded formulations business. This segment was a key driver of profitability, with its EBITDA margin expanding by 155 basis points. Overall company profitability also improved, with the EBITDA margin growing from 35% to 36%, resulting in an EBITDA of Rs. 277 crore. The company's net profit (PAT) was particularly strong, reaching Rs. 126 crore, which represents a significant 41% growth year-over-year and a healthy margin of 16.2%.
The business highlights further underscore this success, noting that 12 of the top 25 mother brands rank in the top five of their respective markets, and five of these brands have revenues exceeding Rs. 100 crore. As of June 30, the company's net debt stands at approximately Rs. 2,317 crore.
Commenting on the results, Amit Bakshi, chairman & managing director of Eris Lifesciences Ltd., said, “Our domestic branded formulations business has delivered a YoY growth of 11% which is over 40% ahead of market growth. Our thesis of reorienting our DBF portfolio to high-growth segments has started delivering results. We are well positioned to ensure continuity of supply in the RHI Penfill segment given the exit of the innovator. Our GLP-1 go-to-market is shaping up as planned and we expect to be among the first players in the market post LoE.”
Krishnakumar Vaidyanathan, executive director & chief operating officer added, “We continue to create value in the acquired Biocon business which posted a Q1 operating margin of 30%, up from 19% at the time of acquisition. Our international CDMO business is well on track to scale up in Western Europe with several marquee customers already signed up. With a 41% PAT/EPS growth in Q1, we are delighted to kick off a 3-year secular cycle of EPS and ROCE acceleration with significant reduction expected in debt, interest expense and tax rates.”
Established in 2007, Eris is the youngest among the Top-20 pharma companies in India. With an annual branded formulations revenue of Rs. 3,000+ crore as per AWACS, Eris has built a diversified presence across specialties and super-specialties such as diabetes, cardiovascular, dermatology, nephrology, neurology, women’s health, oncology and critical care. Eris manufactures a wide range of prescription products across several dosage forms including oral solids, oral liquids, softgels, ointments, sprays & gels, sterile injectables and biologics in its 6 manufacturing facilities, and markets these products across India through a network of 5,000 stockists and 5,00,000+ retail pharmacies.
Eris’ revenue and operating profit have grown 2.6 times in the last 5 years, with FY 25 revenue of Rs. 2,894 crore. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of Rs. 4,000 crore over the last 3 years.
|